DRUGS maker GlaxoSmithKline plans to invest up to £60million (about R802million) over 10 years to improve research, development and access to Aids drugs in Africa, the company said yesterday.
DRUGS maker GlaxoSmithKline plans to invest up to £60million (about R802million) over 10 years to improve research, development and access to Aids drugs in Africa, the company said yesterday.
It has also agreed a new free voluntary licensing agreement for Aids drug abacavir, or Ziagen, with South African generic drugs maker Aspen Pharmacare, in which it has a 16percent stake.
Glaxo took a lead in February by promising to place many of its patents on drugs for tropical diseases into a free "pool".
The company stopped short of offering patents on medicines for HIV-Aids, which it does not consider to be a neglected disease. - Reuters
Glaxo to invest in Aids drugs
DRUGS maker GlaxoSmithKline plans to invest up to £60million (about R802million) over 10 years to improve research, development and access to Aids drugs in Africa, the company said yesterday.
DRUGS maker GlaxoSmithKline plans to invest up to £60million (about R802million) over 10 years to improve research, development and access to Aids drugs in Africa, the company said yesterday.
It has also agreed a new free voluntary licensing agreement for Aids drug abacavir, or Ziagen, with South African generic drugs maker Aspen Pharmacare, in which it has a 16percent stake.
Glaxo took a lead in February by promising to place many of its patents on drugs for tropical diseases into a free "pool".
The company stopped short of offering patents on medicines for HIV-Aids, which it does not consider to be a neglected disease. - Reuters